摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-t-Butyl-3,6-dimethylpyrazine

中文名称
——
中文别名
——
英文名称
2-t-Butyl-3,6-dimethylpyrazine
英文别名
3-tert-butyl-2,5-dimethylpyrazine
2-t-Butyl-3,6-dimethylpyrazine化学式
CAS
——
化学式
C10H16N2
mdl
——
分子量
164.25
InChiKey
VUNCKJZOEHHUEF-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.3
  • 重原子数:
    12
  • 可旋转键数:
    1
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.6
  • 拓扑面积:
    25.8
  • 氢给体数:
    0
  • 氢受体数:
    2

文献信息

  • HETEROCYCLIC COMPOUNDS AND USES THEREOF
    申请人:INFINITY PHARMACEUTICALS, INC.
    公开号:US20130267521A1
    公开(公告)日:2013-10-10
    Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.
    本发明描述了调节激酶活性的化合物和药物组合物,包括PI3激酶活性,以及用于治疗与激酶活性相关的疾病和状况的化合物、药物组合物和方法,包括PI3激酶活性。
  • Nicotinamide Derivatives
    申请人:Blake Tanisha D.
    公开号:US20080146569A1
    公开(公告)日:2008-06-19
    The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts and solvates thereof, wherein the substituents are as defined herein, compositions containing such compounds and the uses of such compounds for the treatment of various diseases and conditions such as asthma.
    本发明涉及公式(I)的化合物及其药用可接受的盐和溶剂化合物,其中取代基如本文所定义,包含这种化合物的组合物以及这种化合物用于治疗各种疾病和状况,如哮喘。
  • PYRIDONE COMPOUNDS AND AGRICULTURAL AND HORTICULTURAL FUNGICIDES CONTAINING THE SAME AS ACTIVE INGREDIENTS
    申请人:MITSUI CHEMICALS AGRO, INC.
    公开号:US20200045968A1
    公开(公告)日:2020-02-13
    Pyridine compounds of Formula (1) are provided: wherein R1, R2, X, Y and Het are defined. The pyridine compounds can be used to treat or prevent plant diseases.
    提供了化合物的化学式(1):其中R1、R2、X、Y和Het均已定义。这些吡啶化合物可用于治疗或预防植物疾病。
  • Piperazine Metabotropic Glutamate Receptor 5 (MGLUR5) Negative Allosteric Modulators For Anxiety/Depression
    申请人:Bursavich Matthew Gregory
    公开号:US20090325964A1
    公开(公告)日:2009-12-31
    The present teachings relate to piperazine metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulators having Formula I: wherein the constituent variables are as defined herein. The present teachings further relate to methods for the preparation of the compounds, and to methods for using the compounds for treatment of diseases and disorders including schizophrenia, paranoia, depression, manic-depressive illness and anxiety.
    本发明涉及具有公式I的哌嗪代谢型谷酸受体5(mGluR5)负向变构调节剂: 其中,组成变量如本文所定义。本发明还涉及制备该化合物的方法,并涉及使用该化合物治疗疾病和障碍的方法,包括精神分裂症、偏执症、抑郁症、躁郁病和焦虑症。
  • Amine Derivatives as Potassium Channel Blockers
    申请人:Harvey Andrew
    公开号:US20140336198A1
    公开(公告)日:2014-11-13
    The present invention relates to compounds useful in the modulation of potassium channel activity in cells, in particular the activity of Kv1.3 channels found in T cells. The invention also relates to the use of these compounds in the treatment or prevention of autoimmune and inflammatory diseases, including multiple sclerosis, pharmaceutical compositions containing these compounds and methods for their preparation.
    本发明涉及用于调节细胞中通道活性的化合物,特别是用于调节T细胞中发现的Kv1.3通道活性的化合物。本发明还涉及使用这些化合物治疗或预防自身免疫和炎症性疾病,包括多发性硬化症,含有这些化合物的制药组合物以及它们的制备方法。
查看更多